業績公告
即時報告
8-K
2026-08-06
Inogen公佈第二季業績 國際收入增14.8% 上調全年EBITDA指引
AI 繁中摘要
Inogen 公佈 2026 年第二季度業績（8-K）📊
美國醫療科技公司 Inogen（Nasdaq: INGN）於 8 月 6 日發佈截至 2026 年 6 月 30 日止第二季度業績。
業績重點：
- 季度總收入 9,510 萬美元，按年增長 3.0%（去年同期 9,230 萬美元）。
- 國際收入 4,130 萬美元，按年大增 14.8%，為主要增長動力；美國銷售及租賃收入則錄得下跌。
- 毛利率 45.5%，高於去年同期的 44.8%；經調整毛利率為 45.6%。
- GAAP 淨虧損 390 萬美元，略好於去年同期的 420 萬美元虧損。
- 經調整 EBITDA 為正數 240 萬美元，按年增長 15.2%。
- 季度經營現金流為正數 290 萬美元。
- 截至 2026 年 6 月 30 日，現金及等價物、有價證券等合共 1.068 億美元，無債務。
營運及策略進展：
- 在加拿大推出 Rove 6 便攜式氧氣濃縮器，拓展國際市場。
- Simeox H SCOPE 中國研究已完成收錄及最後病人到訪（LPLV），預計 2026 下半年公佈統計分析結果。
- 發表 QuOTE 評估工具，簡化長期氧氣治療（LTOT）病人監測。
- 委任 Andy Reding 為首席營運官，加強管理團隊。
展望：
- 公司上調 2026 全年經調整 EBITDA 指引至約 400 萬美元，較 2025 年的 270 萬美元增長 48.1%。
- 全年收入指引更新為 3.55 億至 3.61 億美元，中位數計按年增長約 3%。
- 第三季度收入預期與去年同期相若，主要受美國銷售渠道結構轉變及國際分銷商入貨時間影響。
投資者影響：
國際業務持續強勁，公司正透過新產品及地區擴張改善盈利能力；經調整 EBITDA 轉正並上調指引屬正面訊號。不過美國市場仍偏軟，加上公司預期第三季收入增長放緩，投資者需留意美國銷售復甦進度及國際業務能否持續帶動整體表現。公司上半年已動用 750 萬美元回購股份，顯示對前景有一定信心。
展開英文正文
EX-99.1 2 ingn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Inogen Announces Second Quarter 2026 Financial Results Reported second quarter revenue of $95.1 million Company raises full-year adjusted EBITDA guidance to approximately $4.0 million BEVERLY, Mass., August 6, 2026 -- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2026. “Our second quarter results demonstrate continued demand for our products and validate the progress of our strategy to expand and diversify Inogen’s respiratory care portfolio,” said Kevin Smith, President and Chief Executive Officer. “We are building momentum through new product launches, gaining traction in key markets, and driving greater operating leverage across the business. As we continue to execute against our strategic priorities, we are diligently prioritizing our investments to balance growth, profitability, and innovation to deliver long-term value for shareholders.” Highlights •Achieved second quarter 2026 revenue of $95.1 million, representing 3.0% year-over-year growth, including international revenue of $41.3 million, an increase of 14.8% year-over-year. •Reported GAAP net loss for the second quarter of 2026 of $3.9 million, compared to a net loss of $4.2 million in the prior-year period. •Delivered second quarter 2026 positive adjusted EBITDA of $2.4 million, an increase of 15.2% year-over-year, and generated $2.9 million of positive operating cash flow in the quarter. •Raised adjusted EBITDA guidance for the full year 2026 to approximately $4.0 million, representing a 48.1% increase from adjusted EBITDA of $2.7 million reported in 2025 and updated full-year revenue guidance to $355 million to $361 million reflecting approximately 3% growth at the midpoint of the range. •Published the Questionnaire for Oxygen Therapy Evaluation (QuOTE) assessment tool in ERJ Open Research, a nine-question questionnaire designed to simplify and standardize Long-Term Oxygen Therapy (LTOT) patient monitoring by assessing symptoms, therapy adherence, side effects, and equipment-related issues during routine clinical visits. •Launched the Rove 6 portable oxygen concentrator in Canada, strengthening Inogen's ongoing international market expansion and bringing its best-in-class oxygen therapy technology to approximately two million Canadians diagnosed with chronic obstructive pulmonary disease. •Completed enrollment and achieved Last Patient Last Visit (LPLV) for the Simeox H SCOPE Study in China, with statistical analysis results expected in the second half of 2026, marking an important milestone in expanding Simeox H into additional large global markets. •Strengthened Inogen’s leadership team with the addition of Andy Reding as Chief Operating Officer, whose extensive respiratory care expertise and deep industry experience will support the Company’s strategic growth initiatives and expansion of its product portfolio. Second Quarter 2026 Financial Results Total revenue in the second quarter of 2026 was $95.1 million, an increase of 3.0% from $92.3 million in the prior-year period, primarily driven by higher demand for portable oxygen concentrators, or POCs, in international markets and the favorable impact of foreign exchange rates. While U.S. sales and rentals remained below the prior-year period, the Company continued to gain traction with U.S. distributors and the expanded product portfolio, reinforcing confidence in its long-term opportunities in the U.S. market. Total gross margin was 45.5% in the second quarter of 2026 compared to 44.8% in the prior-year period. Adjusted gross margin improved by 65 basis points to 45.6% compared to 44.9% in the prior-year period due to improvements in cost of revenue. GAAP net loss for the second quarter of 2026 was $3.9 million compared to a net loss of $4.2 million in the prior-year period. Adjusted net loss improved $0.6 million year-over-year to less than $0.1 million in the second quarter of 2026, compared with an adjusted net loss of $0.7 million in the prior-year period. Adjusted EBITDA was a positive $2.4 million in the second quarter of 2026, compared to a positive $2.1 million in the prior-year period, an improvement of $0.3 million. Cash, cash equivalents, marketable securities, and restricted cash were $106.8 million as of June 30, 2026, with no debt outstanding. The Company repurchased 1,145,150 shares of its common stock in the first half of 2026 for consideration of $7.5 million under the share repurchase program that was announced in the first quarter of 2026. Reconciliations of adjusted gross margin, adjusted EBITDA, and adjusted net loss for the three and six months ended June 30, 2026 and 2025 are in the financial schedules that are a part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures.” Third Quarter and Full Year 2026 Financial Outlook Inogen expects third quarter 2026 revenue to be approximately in line with third quarter 2025 revenue, reflecting the continued U.S. sales channel mix shift as well as the timing impact of select international distributor inventory purchases. For the full year 2026, Inogen now expects reported revenue in the range of $355 million to $361 million, reflecting approximately 3% growth at the midpoint of the range relative to the Company’s 2025 revenue. The Company now expects full year 2026 adjusted EBITDA of approximately $4.0 million representing a 48.1% increase from $2.7 million reported in 2025. The Company has not provided a reconciliation of forward-looking Adjusted EBITDA to the most directly comparable GAAP measure because certain items that impact net income are uncertain or outside the Company's control and cannot be reasonably predicted without unreasonable effort. Quarterly Conference Call Information On August 6, 2026, the Company will host a conference call at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. Individuals interested in listening to the conference call may do so by dialing: U.S. domestic callers (877) 841-3961Non-U.S. callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. This webcast will also be archived on the website for six months. A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through August 13, 2026. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13761255. Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. About Inogen Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease. For more information, please visit www.inogen.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial outlook, growth strategies, anticipated operational results, and guidance, are forward-looking statements. Words such as “aims,” “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to Inogen’s 2026 third quarter and full year financial guidance; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the period ended December 31, 2025, its Quarterly Report on Form 10-Q for the period ended March 31, 2026, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law. Non-GAAP Financial Measures Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three and six months ended June 30, 2026, and June 30, 2025. Management believes that these non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of Inogen’s core operating results. Management uses these non-GAAP measures to compare Inogen’s performance relative to forecasts and strategic plans, to benchmark Inogen’s performance externally against competitors, and for certain compensation decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Inogen's operating results as reported under U.S. GAAP. Inogen encourages investors to carefully consider its results under U.S. GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between U.S. GAAP and non-GAAP results are presented in the accompanying tables of this release. [email protected] Consolidated Statements of Comprehensive Loss (unaudited) (amounts in thousands, except share and per share amounts) Three months endedJune 30, Six months endedJune 30, 2026 2025 2026 2025 Revenue Sales revenue $ 83,525 $ 79,172 $ 155,929 $ 147,642 Rental revenue 11,559 13,105 24,264 26,915 Total revenue 95,084 92,277 180,193 174,557 Cost of revenue Cost of sales revenue 44,949 43,469 85,126 81,552 Cost of rental revenue, including depreciation of $2,475 and $3,017 for the three months ended and $5,103 and $6,051 for the six months ended, respectively 6,863 7,467 13,932 15,292 Total cost of revenue 51,812 50,936 99,058 96,844 Gross profit 43,272 41,341 81,135 77,713 Operating expense Research and development 5,871 5,209 10,968 9,243 Sales and marketing 24,824 25,390 49,427 49,147 General and administrative 17,673 16,871 35,172 33,108 Total operating expense 48,368 47,470 95,567 91,498 Loss from operations (5,096 ) (6,129 ) (14,432 ) (13,785 ) Other income Interest income, net 861 1,123 1,741 2,152 Other income, net 231 701 189 1,057 Total other income, net 1,092 1,824 1,930 3,209 Loss before benefit for income taxes (4,004 ) (4,305 ) (12,502 ) (10,576 ) Benefit for income taxes (154 ) (153 ) (328 ) (250 ) Net loss (3,850 ) (4,152 ) (12,174 ) (10,326 ) Other comprehensive (loss) income, net of tax Change in foreign currency translation adjustment (350 ) 3,926 (1,195 ) 5,781 Change in net unrealized (losses) gains on foreign currency hedging (142 ) 36 (179 ) (696 ) Less: reclassification adjustment for net gains (losses) included in net loss 164 (606 ) 201 (739 ) Total net change in unrealized gains (losses) on foreign currency hedging 22 (570 ) 22 (1,435 ) Change in net unrealized (losses) gains on marketable securities (11 ) 42 6 42 Total other comprehensive (loss) income, net of tax (339 ) 3,398 (1,167 ) 4,388 Comprehensive loss $ (4,189 ) $ (754 ) $ (13,341 ) $ (5,938 ) Basic net loss per share attributable to common stockholders (1) $ (0.14 ) $ (0.15 ) $ (0.45 ) $ (0.40 ) Diluted net loss per share attributable to common stockholders (1) (2) $ (0.14 ) $ (0.15 ) $ (0.45 ) $ (0.40 ) Weighted average number of shares used in calculating net loss per share attributable to common stockholders: Basic shares of common stock 27,045,095 26,962,465 27,183,000 26,068,421 Diluted shares of common stock 27,045,095 26,962,465 27,183,000 26,068,421 (1) Reconciliations of net loss attributable to common stockholders basic and diluted can be found in Inogen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the Securities and Exchange Commission. (2) Due to a net loss for the three and six months ended June 30, 2026 and June 30, 2025, diluted loss per share is the same as basic. Consolidated Balance Sheets (unaudited) (amounts in thousands) June 30,2026 December 31,2025 Assets Current assets Cash and cash equivalents $ 87,276 $ 103,729 Marketable securities 18,263 15,848 Restricted cash 1,303 1,289 Accounts receivable, net 46,157 38,863 Inventories 28,633 25,969 Prepaid expenses and other current assets 12,504 12,601 Total current assets 194,136 198,299 Property and equipment, net 31,781 36,362 Goodwill 10,395 10,698 Intangible assets, net 27,447 30,763 Operating lease right-of-use asset 14,914 16,501 Other assets 6,899 6,002 Total assets $ 285,572 $ 298,625 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued expenses $ 39,678 $ 33,941 Accrued payroll 12,796 10,629 Warranty reserve - current 10,414 10,116 Operating lease liability - current 3,253 3,163 Deferred revenue - current 4,723 5,503 Income tax payable — 183 Total current liabilities 70,864 63,535 Long-term liabilities Warranty reserve - noncurrent 17,961 18,194 Operating lease liability - noncurrent 12,541 14,313 Deferred revenue - noncurrent 2,857 3,603 Deferred tax liability 6,485 6,749 Total liabilities 110,708 106,394 Stockholders' equity Common stock 27 27 Additional paid-in capital 359,519 363,545 Accumulated deficit (187,758 ) (175,584 ) Accumulated other comprehensive income 3,076 4,243 Total stockholders' equity 174,864 192,231 Total liabilities and stockholders' equity $ 285,572 $ 298,625 Condensed Consolidated Cash Flow (unaudited) (amounts in thousands) Six months endedJune 30, 2026 2025 Cash flows from operating activities Net loss $ (12,174 ) $ (10,326 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 9,601 10,405 Loss on rental units and other assets 1,261 1,655 Provision for sales revenue returns and doubtful accounts 3,845 3,248 Provision for inventory losses 681 447 Stock-based compensation expense 3,721 4,440 Deferred income taxes (73 ) 80 Other 104 267 Changes in operating assets and liabilities (1) (10,705 ) (22,656 ) Net cash used in operating activities (3,739 ) (12,440 ) Cash flows from investing activities Purchases of available-for-sale securities (13,079 ) (18,703 ) Maturities of available-for-sale securities 10,670 — Investment in property and equipment (921 ) (976 ) Production and purchase of rental equipment (1,779 ) (4,932 ) Net cash used in investing activities (5,109 ) (24,611 ) Cash flows from financing activities Proceeds from employee stock purchases 373 489 Payment of employment taxes related to vesting of restricted stock units (622 ) (570 ) Repurchases of common stock (7,498 ) — Payments of accrued earnout — (3,178 ) Proceeds from issuance of common stock from securities purchase agreement — 27,210 Net cash (used in) provided by financing activities (7,747 ) 23,951 Effect of exchange rates on cash 156 642 Net decrease in cash, cash equivalents, and restricted cash $ (16,439 ) $ (12,458 ) (1) Includes $9,822 of the operating activity portion of the earnout liability payment related to the Physio-Assist acquisition for the six months ended June 30, 2025. Supplemental Financial Information (unaudited) (in thousands, except units and patients) Constant Three months ended Currency June 30, Change 2026 vs. 2025 Change (1) Revenue by geographic region 2026 2025 $ % % U.S. sales $ 42,272 $ 43,249 $ (977 ) -2.3 % -2.3 % International sales 41,253 35,923 5,330 14.8 % 8.3 % U.S. rentals 11,559 13,105 (1,546 ) -11.8 % -11.8 % Total revenue $ 95,084 $ 92,277 $ 2,807 3.0 % 0.6 % Additional financial measures Portable units sold 53,300 47,600 Net rental patients as of period-end 45,500 50,400 Constant Six months ended Currency June 30, Change 2026 vs. 2025 Change (1) Revenue by geographic region 2026 2025 $ % % U.S. sales $ 77,008 $ 79,734 $ (2,726 ) -3.4 % -3.4 % International sales 78,921 67,908 11,013 16.2 % 7.2 % U.S. rentals 24,264 26,915 (2,651 ) -9.8 % -9.8 % Total revenue $ 180,193 $ 174,557 $ 5,636 3.2 % -0.2 % Additional financial measures Portable units sold 99,600 89,400 Net rental patients as of period-end 45,500 50,400 (1) Represents a non-GAAP financial measure. Reconciliation of U.S. GAAP to Non-GAAP Financial Measures (unaudited) (in thousands, except per share amounts) Three months endedJune 30, Six months endedJune 30, Non-GAAP EBITDA and Adjusted EBITDA 2026 2025 2026 2025 Net loss (GAAP) $ (3,850 ) $ (4,152 ) $ (12,174 ) $ (10,326 ) Non-GAAP adjustments: Interest income, net (861 ) (1,123 ) (1,741 ) (2,152 ) Benefit for income taxes (154 ) (153 ) (328 ) (250 ) Depreciation and amortization 4,697 5,216 9,601 10,405 EBITDA (non-GAAP) (168 ) (212 ) (4,642 ) (2,323 ) Stock-based compensation expense 1,771 2,293 3,721 4,440 Restructuring-related charges 214 — 1,130 — Stockholder engagement and proxy defense costs (1) 580 — 789 — Adjusted EBITDA (non-GAAP) $ 2,397 $ 2,081 $ 998 $ 2,117 Three months ended June 30, 2026 Non-GAAP Financial Metrics Gross Profit Operating Expense Loss from Operations Net Loss Diluted EPS Financial Results (GAAP) $ 43,272 $ 48,368 $ (5,096 ) $ (3,850 ) $ (0.14 ) Reported percent net sales 45.5 % 50.9 % (5.4 %) (4.0 %) Non-GAAP adjustments: Amortization of intangibles — 1,252 1,252 1,252 0.05 Stock-based compensation 73 1,698 1,771 1,771 0.07 Restructuring-related charges — 214 214 214 0.01 Stockholder engagement and proxy defense costs (1) — 580 580 580 0.02 Income tax impact of adjustments (2) — — — — — Adjusted $ 43,345 $ 44,624 $ (1,279 ) $ (33 ) $ — Adjusted percent net sales 45.6 % 46.9 % (1.3 %) (0.0 %) Three months ended June 30, 2025 Non-GAAP Financial Metrics Gross Profit Operating Expense Loss from Operations Net Loss Diluted EPS Financial Results (GAAP) $ 41,341 $ 47,470 $ (6,129 ) $ (4,152 ) $ (0.15 ) Reported percent net sales 44.8 % 51.4 % (6.6 %) (4.5 %) Non-GAAP adjustments: Amortization of intangibles — 1,209 1,209 1,209 0.04 Stock-based compensation 129 2,164 2,293 2,293 0.09 Income tax impact of adjustments (2) — — — — — Adjusted $ 41,470 $ 44,097 $ (2,627 ) $ (650 ) $ (0.02 ) Adjusted percent net sales 44.9 % 47.8 % (2.8 %) (0.7 %) Six months ended June 30, 2026 Non-GAAP Financial Metrics Gross Profit Operating Expense Loss from Operations Net Loss Diluted EPS Financial Results (GAAP) $ 81,135 $ 95,567 $ (14,432 ) $ (12,174 ) $ (0.45 ) Reported percent net sales 45.0 % 53.0 % (8.0 %) (6.8 %) Non-GAAP adjustments: Amortization of intangibles — 2,548 2,548 2,548 0.09 Stock-based compensation 255 3,466 3,721 3,721 0.14 Restructuring-related charges — 1,130 1,130 1,130 0.04 Stockholder engagement and proxy defense costs (1) — 789 789 789 0.03 Income tax impact of adjustments (2) — — — — — Adjusted $ 81,390 $ 87,634 $ (6,244 ) $ (3,986 ) $ (0.15 ) Adjusted percent net sales 45.2 % 48.6 % (3.5 %) (2.2 %) Six months ended June 30, 2025 Non-GAAP Financial Metrics Gross Profit Operating Expense Loss from Operations Net Loss Diluted EPS Financial Results (GAAP) $ 77,713 $ 91,498 $ (13,785 ) $ (10,326 ) $ (0.40 ) Reported percent net sales 44.5 % 52.4 % (7.9 %) (5.9 %) Non-GAAP adjustments: Amortization of intangibles — 2,348 2,348 2,348 0.09 Stock-based compensation 296 4,144 4,440 4,440 0.17 Income tax impact of adjustments (2) — — — — — Adjusted $ 78,009 $ 85,006 $ (6,997 ) $ (3,538 ) $ (0.14 ) Adjusted percent net sales 44.7 % 48.7 % (4.0 %) (2.0 %) Three months endedJune 30, Six months endedJune 30, Non-GAAP Free Cash Flow 2026 2025 2026 2025 Operating Cash Flow $ 2,946 $ 4,350 $ (3,739 ) $ (12,440 ) Capital Expenditures (1,919 ) (3,870 ) (2,700 ) (5,908 ) Free Cash Flow $ 1,027 $ 480 $ (6,439 ) $ (18,348 ) (1) Stockholder engagement and proxy defense costs include third-party advisory, legal, and other professional fees. (2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for 2026 and 2025.